Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$67.36 USD

67.36
116,783

+0.11 (0.16%)

Updated May 6, 2024 04:00 PM ET

After-Market: $67.37 +0.01 (0.01%) 6:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

by Zacks Equity Research

The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.

Vincerx (VINC) Tumbles on Results From Cancer Therapy Study

by Zacks Equity Research

Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.

Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data

by Zacks Equity Research

Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

by Zacks Equity Research

The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.

Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

by Zacks Equity Research

A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

by Zacks Equity Research

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Bausch (BHC) Starts Litigation Against Amneal for Xifaxan

by Zacks Equity Research

Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.

MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why

by Zacks Equity Research

MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

by Zacks Equity Research

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.

AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

by Zacks Equity Research

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.

Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in ANI (ANIP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Gritstone (GRTS) Plummets 58% in a Week: Here's Why

by Zacks Equity Research

Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.

Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%

by Zacks Equity Research

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

by Zacks Equity Research

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA

by Zacks Equity Research

Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

by Zacks Equity Research

Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.

Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder

by Zacks Equity Research

Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

by Zacks Equity Research

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $66.72 in the latest trading session, marking a -1.69% move from the prior day.

Disc Medicine (IRON) Down on Mixed Results From AURORA Study

by Zacks Equity Research

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.